Hybridization-Based Solid Tumor Panel Delivers Consistent, Reliable Results

The panel was fully validated on formalin-fixed, paraffin-embedded (FFPE) samples.

The content of the panel has been defined by cancer experts, covering key genes for a range of cancer types including breast, prostate, ovarian, lung, and colorectal. All exons of these genes are fully covered, including mutation hotspots, enabling both detection and discovery of known and novel variants respectively.

The hybridization-based SureSeq Solid Tumor Panel minimizes polymerase chain reaction (PCR) bias and duplications commonly associated with alternative enrichment methodologies, enabling greater run-to-run consistency. This is particularly important in situations where there is a limited sample or where the ability to detect minor allele frequencies is required, such as in heterogeneous tumor samples. Such sample types require a highly uniform and sensitive enrichment and OGT’s expert bait design ensures this by providing efficient and improved uniformity of coverage of the targeted regions, enabling all variants to be called with maximum confidence.

Providing easy access to meaningful data, the SureSeq Solid Tumor Panel comes with OGT’s Variant Analysis Report, equipping researchers with the freedom to explore and retrospectively interrogate data with additional or new selection criteria, without the need for additional in-house bioinformatics resource. Using the report, data can be easily filtered by numerous parameters, including gene, depth of coverage, somatic variants and predicted effect on the protein. In addition, all variants are fully annotated with links to various databases.

OGT's Cytocell, CytoSure and Genefficiency range of fluorescence in situ hybridization (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.

Related Links:
Oxford Gene Technology